when will oral glp-1 be available The Food and Drug Administration has approved the first weight loss drug by Eli Lilly, called Foundayo A new chapter in GLP-1

Clinical trial data from large cardiovascular outcome studiesincluding LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide)have not demonstrated increased fracture risk among patients taking GLP-1 receptor agonists compared with placebo

Ensuring Success Through Technology, Science, Scale, and Service Successful clinical trials require more than just technology

Management options may include dose adjustment, temporary treatment interruption, addressing contributing factors (such as optimizing management of gastrointestinal side effects), or considering alternative weight management strategies if symptoms persist and significantly impact quality of life

Dupont J, Vercauteren L, Amini N, Lapauw L, De Schaepdryver M, Poesen K, Dedeyne L, Verschueren S, Tournoy J, Koppo K, Gielen E